Member Info for Albinio74

2021 haha

Strong start to 2020, Chronocort will (on anticipated approval) plug straight into these established sales and distribution set ups, great stuff.

All I can find is this, https://consult.environment-agency.gov.uk/psc/regulation-of-rathlin-energy-s-west-newton-b/

"Providing a business can show that the proposed activities meet all the legal requirements, including environmental, technological and health requirements, then we are legally obliged to issue a permit, even if some people do not approve of the decision."

Looks like they can only refuse it on technical grounds which you would have thought have been satisfied during work, application's and preparation so far.

No indication of timescales.

Tricky to get absolute time lines for regulatory processes, decisions always subject to variable outcomes and we are in a pretty weird time which is unlikely to help but hopeful of European news on Chronocort in Q1, most holders optimistic of a positive outcome but not guaranteed.

https://www.hardmanandco.com/research/corporate-research/clarity-for-chronocort-regulatory-pathway/

https://otp.tools.investis.com/clients/uk/diurnal_limited/rns/regulatory-story.aspx?cid=1282&newsid=1395604

https://otp.tools.investis.com/clients/uk/diurnal_limited/rns/regulatory-story.aspx?cid=1282&newsid=1383495

HNY all - hoping strong Alkindi sales news, Chronocort European recommendation for approval and maybe a Japan deal can get DNL off to a cracking start in 2021. 8pm on NYE shouldn't be thinking not shares I guess - see you on the other side.

To be fair S&S have mentioned getting it producing before. That may not mean developing the whole license however.

Been holding for some time now here and while I thought the type of news we received today would give the sp an instant significant and sustainable uplift, at the name time I am not letting the market reaction dampen my enthusiasm for the news, at the end of the day if they have something of huge value it has to be recognised eventually in the share price, barring some very strange circumstances.

Well chuffed with today and the outlook.

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-availability-orphan-drug-alkindir#

Hi Hunsen,

Over time I have learnt to try and avoid personal stuff and steer clear of threads that head that way, happy chew over opinions and facts, positive and negative - that is the point of these BBs after all.

Actually your comments made me go back through RNS output, interviews snd varying information (and of course the excellent posts by Balanced66) - helped strengthen my long term view actually and a healthy thing to do for investors from time to time while considering other perspectives.

That is my feeling too, Alkindi alone can support and advance the sp with market/sales growth, Chronocort has a good chance of progressing but no way I would count any chickens. Ditest very interesting but of course very early to be trying to factor that into the current share price/company activity.

I was struggling to understand a clear logic in Hunsen's posts and sharing of the podcast. Your posts answered rather better than my blurb.

Wow balanced - great set of posts and I bow to your very thorough answers to Hunsen's concerns - thanks. Worth bookmarking the links and taking screen shots of the posts.

https://bit.ly/2IQdgYI

You may find this brief interview regarding the Chronocort phase 3 trials useful https://www.***************************/interview-diurnal-group-unexpected-phase-iii-trial-outcome/412760360

Hi Hunsen, not meaning to be needlessly argumentative but a touch of cake and eat it in your responses.

1. I have not evaded anything, I feel my point is crystal clear, sorry if confusing to you, but put it another way, Chronocort is a much bigger market and Diurnal was getting popular investment press coverage at the time, Investors Chronicle for example, that is why the sp was pushed to £2 + and why the crash was so hard, the current sp rise has been driven by Alkindi actually going live in the market, so a retrace to 20p on bad Chronocort news seems very unlikely as the circumstances are very different.

2. I was not referencing cash balance specifically, more that they had no near term income so any cash would be eaten through quickly ( I believe they had around £15m), currently they have £15m and a product selling with growth potential.

3.i see nothing in my point to debate, some risk, less at stage 3 v stage 1.

4. I believe more deals/regions will come and that sales will grow, peak sales straight off the bat seems very unlikely.

The response to the phase 3 issues were anything but vague, they felt the way the figures were recorded and presented caused the problem and would resubmit application if talks with the governing bodies went well, we can therefore deduce the discussions were productive hence resubmission.

That is your more in-depth interpretation of events, I don't think the podcast snippet offers any of that.

I am unsure on your suggestion that they are hiding costs, and more importantly the relevance to the commercial success of the company and treatments they are working towards.

What I would point out is -:

1. The crash back to 20 odd p was pre Alkindi deals/regulatory approvals.

2. At a time the company was clearly in need of cash.

3. I am not saying being at phase 3 totally removes risk, but it partially derisks as an inevitable and undeniable consequence of being at an advanced stage of development.

4. The commercial development of Alkindi is in it's infancy, so seems likely we will see more deals with different partners in more regions financially underpin the company further, especially based on Eton Pharmaceutical's recent bullish update (we will see).

Also worth noting the company comments following the Chronocort European phase 3 issues, they remained confident of carrying it through to being a viable treatment option, were surprised by the results v earlier phase studies and have engaged with the authorities to resolve the issues, risk free certainly not, but room for cautious optimism.

No, they have a valid point per drug, as an assessment of a company the podcast is basically drivel.

If they were motif where the fortunes of the company hinged on a single outcome, fine.

They now have a bonified asset (Alkindi) no different really to an operating mine with a JORC.

If they sold Alkindi tomorrow what would be the price? Their chartcast does not acknowledge this, therefore zero research value to say pharma carries risk.

The risk/reward ratio is in Chronocort and Ditest - we will see, not long before we get news (I hope) on Chronocort - but phase iii more derisked v phase i - how do you vlaue that?

If someone can't distinguish between the two then they should not invest until all in the bag, as with mining companies, do you minimise risk or maximise potential reward, or a bit of both (most sensible IMO).

Still don't follow the logic beyond stating the obvious RE risk in pharma's and shares in general, but while failing to acknowledge established assets and near term associated commercial returns the.podcast snippet is of zero value.

Evidence to the contrary welcome.

Thanks for posting although their logic is sort of lost on me, it is a binary outcome per "drug", not per company (unless they are dependent on one project) - recovery over the second half of this year actually based on numerous factors including FDA approval for Alkindi. That is a pretty hefty block to underpin the current price with.

Being a bit brutal, pointless them covering Diurnal with no info based purely in charts - in a nutshell they are saying the price is stuck in trading range and pharma stocks are risky/volatile based on governing body approvals etc, as illustrated in the company (Diurnal) history.

and how long is "the fullness of time" ha, tickled me.

To be fair Olly your comments came across very much like telling someone still running and half way through a marathon that they have failed to complete the event.

Good to hear Corallion not completely off the Reabold map and seems an interesting bit of news today. One to have a mooch and ponder over.

Thanks for sharing the link HunSen - Ditest has great potential, current position underpinned by Alkindi and Chronocort news not far away.

We are now turning our focus to building out a leading orphan drug commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Early interest in ALKINDI SPRINKLE from physicians and caregivers has been very strong and has reiterated the significant need for the product.”

Eton anticipates having commercial availability of ALKINDI SPRINKLE by the end of November. The company’s ALKINDI SPRINKLE sales representatives have been hired, fully trained, and have begun engaging with pediatric endocrinologists. Initial interest from physicians, caregivers, and patients has been very strong and Eton expects the product to exceed the company’s original sales forecast for 2021.